无锡祥生医疗科技股份有限公司 2025年第二次临时股东会决议公告

Core Points - The company held its second extraordinary general meeting of shareholders on October 17, 2025, with no rejected proposals [2][4] - The meeting was legally convened and conducted, with all procedures in compliance with the Company Law and the company's articles of association [2][7] - The board of directors and all directors confirmed the accuracy and completeness of the announcement content [1] Group 1: Meeting Details - The meeting took place at the company's conference room in Wuxi, China [2] - All six current directors attended the meeting, with some present in person and others via communication methods [3] - The meeting was chaired by Mr. Zhou Feng, who was elected by the attending directors [2][3] Group 2: Resolutions Passed - Three key resolutions were passed, including the approval of the 2025 Restricted Stock Incentive Plan and its management measures [4][5] - The resolutions required a two-thirds majority of the votes from shareholders present at the meeting [5][6] - Separate voting was conducted for minority investors on the resolutions [6] Group 3: Insider Trading Self-Examination - The company conducted a self-examination regarding insider trading related to the 2025 Restricted Stock Incentive Plan [9][10] - Only one incentive object was found to have traded the company's stock within six months prior to the plan's announcement, and this was based on independent investment decisions [10][11] - The company confirmed that no insider information was leaked and that all necessary confidentiality measures were taken [11]